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STUDY OF SERUM N-TELOPEPTIDE, A BONE RESORPTIVE 
BIOMARKER IN POST MENOPAUSAL WOMEN 
           ABSTRACT 
INTRODUCTION: 
            Osteoporosis is a metabolic bone disorder characterized by low bone mass 
associated with micro architectural deterioration of bone tissue leading to enhanced bone 
fragility and an increase in fracture risk. Postmenopausal osteoporosis is characterized by 
a hormone dependent acceleration of bone loss that occurs after menopause. Serum N-
TELOPEPTIDE, a bone resorptive biomarker helps to identify the post menopausal 
woman with high bone turnover rate and thereby predict their future fracture risk. 
AIMS AND OBJECTIVES: 
           The AIM of the study is to measure S.N-Telopeptide, in postmenopausal 
women  and to evaluate the relationship between  N-Telopeptide and S.Estrogen. 
MATERIALS AND METHODS: 
Study group included 50 postmenopausal women aged 50-70 years who were 
not previously diagnosed as osteoporosis and who had BMD T-score  ≥ - 2.5 and T-
score between -1.0 to -2.5. Control group include50 premenopausal women aged 25-
35 years. S.N-Telopeptide  and S.Estradiol were measured by ELISA method. 
RESULTS: 
The mean range of S.N-Telopeptide in the study group (101.47 nmolBCE/L) is  
significantly higher than the control group mean (17.35 nmol BCE/L) and the p value 
is statistically significant. Pearsons correlation studies showed a negative correlation 
between N-telopeptide and Estrogen, BMD, BMI and a positive correlation between 
N-Telopeptide and Total Alkaline Phosphatase which is statistically significant. 
CONCLUSION: 
 This study shows that there is a significant increase in serum N.Telopeptide 
level in postmenopausal women and it correlates well with the degree of osteoporosis. 
KEY WORDS: 
  N-Telopeptide, Post menopausal osteoporosis, Estrogen, BMD, BMI.  
 
 
       
  
INTRODUCTION 
Osteoporosis is a metabolic bone disorder characterized by low bone mass 
associated with micro architectural deterioration of bone tissue leading to enhanced 
bone fragility and an increase in fracture risk.1 
In the new millenium, as we reap the stupendous advances in medical 
science we are faced with new problems of "ageing". With increase in life 
expectancy osteoporosis is one of the major public health problem that increases 
the morbidity and mortality in postmenopausal women. 2 
Osteoporosis is a silent epidemic. Nearly 14% of postmenopausal women 
and 8% of men above 50 years of age have osteoporosis.3 The hallmark of 
osteoporosis is, in its predisposition to fracture following relatively a minor 
trauma. At the age of 50, women have a life time fracture risk of about 40%. 
Postmenopausal osteoporosis is characterized by a hormone dependent 
acceleration of bone loss that occurs after menopause. In regard to postmenopausal 
osteoporosis decreased quantity of sex hormone mainly "estrogen" is the prime 
factor that results in unbalanced bone remodelling. Decreased estrogen level results 
in increased production of cytokines like IL-1, IL-6 and TNF by blood monocyte 
and bone marrow cells. These cytokines, in turn, mediates osteoclast recruitment 
and activity, by increasing the levels of  RANK and RANK-L and decreasing the 
activity of Osteoprotegrin. Compensatory osteoblastic activity occurs, but it does 
  
not keep in pace, leading to osteoporosis.4, 5  
Early the diagnosis will reduce the morbidity and mortality rate, but the 
diagnosis of osteoporosis is complicated by the fact that routine x-rays are not 
sensitive enough to pick up osteoporosis at an early age. It has been estimated that 
nearly 40% of skeletal bone mass is lost before the x-ray shows the sign of 
osteopenia. Further, osteoporosis does not reveal any consistent metabolic 
abnormality detected by standard laboratory tests and certainly, it is very difficult 
to predict a fracture at a given time in specific person.6 
Diagnosis of osteoporosis is made clinically by quantifying the bone mineral 
density. Recently, new bone turnover markers have been used in attempt to get a 
better insight into bone micro architecture and they appear as a promising tool for 
defining the skeletal status of post menopausal women. 
Bone turn over markers are useful inexpensive tools for studying bone 
metabolism in population studies and they also predict fracture risk independent of 
bone mineral density - High bone turnover per se, can disrupt trabecular 
architecture by increasing the incidence of trabecular  perforation and buckling, 
thus reducing bone strength without necessarily affecting bone mineral density 
substantially. 7 
N-TELOPEPTIDE is a stable degradation end product from type-1 collagen. 
In bone type -1 collagen is formed by two α (1) and one α (2) chains stabilised by 
  
the formation of pyridinium cross links, pyridinoline and deoxypyridinoline in the 
telopeptide region. During bone resorption, type-1 collagen is degraded, yielding 
smaller fragments like N-Telopeptide, C-Telopeptide, pyridinoline and 
deoxypyridinoline in circulation making these fragments available as markers of 
bone resorption.8  
The present study on serum N-TELOPEPTIDE, a bone resorptive biomarker 
helps to identify the post menopausal woman with high bone turnover rate and 
thereby predict their future fracture risk. The N-Telopeptide assay measures N-
Telopeptide linked pyridinoline and deoxypyridinoline in serum and the results are 
expressed as bone collagen equivalents. 
 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
  Osteoporosis is a metabolic disorder characterised by decreased bone mass 
and increased susceptibility to fractures secondary to trivial trauma.  Osteoporosis 
is characterised by an altered balance between  resorption and  formation of bone 
which leads to gradual decline in bone mass and the decrease in the amount of 
mineralisation of bone. The   ratio between mineral and collagen  is normal. 
             Major consequences of osteoporosis include fragile  bones and increased 
susceptibility to fractures such as 
              Vertebral compression fracture. 
              Fracture neck of femur.  
              Colles fracture.9 
 In early nineteenth century Sir. Astley cooper , a distinguished English 
surgeon noted-“the lightness and softness that (bones) acquire in the most 
advanced stages of life” and this state of bone favours much, the production of 
fractures. Johann lobstein coined the term “osteoporosis”. In 1940, “Fuller 
Albright” the American physician and endocrinologist  described “Postmenopausal 
osteoporosis” as a sequelae of impaired formation of bone due to deficiency of  
estrogen. 10 
  
 
WHO STUDY GROUP ASSESSMENT OF FRACTURE RISK AND ITS 
APPLICATION TO SCREENING FOR POST MENOPAUSAL 
OSTEOPOROSIS. 
WHO TECHNICAL REPORT SERIES : 843- 1994  11 
CATEGORY BONE MINERAL DENSITY T SCORE 
Normal ≤ 1SD below average peak BMD of young adult         _ 
Osteopenia 1.0-2.5 SD below average peak BMD of young adult. -1.0 to -2.5 
Osteoporosis ≥2.5 SD below the average peak  BMD of young adult. ≥ -2.5 
Severe Osteoporosis 
≥2.5 SD below the mean 
BMD of young adult and 
history of one or more non 
traumatic fracture. 
≥ -2.5 
      
  
WORLD HEALTH ORGANISATION describes osteoporosis is a condition 
in which  bone mineral density  falls below 2.5 standard deviation(S.D.) from the 
mean of a young adult of the same sex. It is also termed as T-Score of -2.5. 
Now the present concept is, Osteoporosis  represents the disorder, in which 
numerous etiological factors  converge resulting in bone loss and breakdown of  
microarchitectural  structure of bone. In osteoporotic patients, various pathogenic  
factors  are  added together  with increased incidence of falls, contribute to a high 
incidence of fragility fractures. 
EPIDEMIOLOGY: 
           As our society is ‘‘ageing” there is considerable shift in the epidemiology of 
Osteoporosis. It is a silent epidemic, but a progressive disease until a fracture 
occurs. There are 325 million individuals over 65 years of age in this world. This 
will increase to over 1500 million by 2050.The increase will be particularly seen in 
Asia.12 
           In developed countries, the fractures related to osteoporosis are estimated to 
affect 30% of women and 12% of men. The immediate mortality is 12% and there 
is a continued increase in mortality of about 20% when compared to age matched 
controls.13 
  
   WHO TECHNICAL REPORT SERIES – 843 predicts a significant increase 
in fracture neck of femur among Asian population over a period of time. By 2050, 
osteoporosis will be a major demographic factor due to changes in life style and 
the increase in survival rate of elderly. 
          The incidence of fracture of hip is likely to rise across the world from 
8,40,000 in 1986 to approximately 6.26 million in 2050 and 7% of these fractures 
are likely to occur in the developing countries. India is likely to have a fracture 
incidence of neck of femur of approximately 1.2 million per year particularly 
among women.14 
OSTEOPOROSIS CURRENT SCENARIO IN INDIA 
          Due to increased life expectancy of Indian population, now it is realised that, 
as in the west, the osteoporotic fractures are the leading cause of morbidity and 
mortality in the elderly. In most western countries, the peak incidence of 
osteoporosis occurs at about 70 – 80 years of age, where as in India it may affect 
those 10 – 20 years younger at the age of 50- 60 years. 
 Based on 2001 census, approximately 163 millions of Indians are above the 
age of 50 and this number is expected to increase to 230 million by 2015. Even 
conservative estimates suggest that, of these, 20% of women and 10 -15% of men 
  
would be osteoporotic. The total affected population would therefore be around 25 
million.15 
BIOCHEMISTRY OF BONE 
 Bone consists of organic, inorganic materials and water in percentage 
composition of 25%, 65%, and 10%  
ORGANIC PHASE 
 INTERCELLULAR MATRIX (21%) 
 BONE CELLS (4%) 
INTERCELLULAR MATRIX 
 COLLAGEN 
 NON COLLAGENOUS PROTEIN 
COLLAGEN 
 Collagen is the primary extracellular portion of the body consisting of three 
polypeptide chains in the form of triple helix. One third of the aminoacid 
composition is glycine, one fifth proline and its derivative hydroxyproline. In 
addition, it contains hydroxylysine.72 
NON COLLAGENOUS PROTEIN 
  
Osteocalcin secreted by osteoblasts constitutes the major non collagenous 
protein in the bone.  It is one of the biomarker of bone formation. Other proteins 
include Matrix Gla protein and osteonectin.   
 
 
 
 
 
  
BONE CELLS : 
 There are four different types of bone cells having specific functions in bone 
formation, resorption and remodelling. 
 
OSTEOPROGENITOR CELLS: 
Osteoprogenitor cell derived from primitive stem cell differentiates into 
osteoblasts and osteocytes. They are found in bone marrow, periosteum and other 
supporting tissues. 16 
  
OSTEOBLASTS: 
 The osteogenic cells in the deep layers of periosteum and of the endosteum  
differentiates in to osteoblasts. Osteoblasts are cuboidal mononuclear cells 15-30 
µmm in diameter. They possess an enzyme called Alkaline phosphatase and they 
have amorphous calcium phosphate. Osteoblasts activate osteoclastic activity. 
Collagenase secreted by osteoblast is responsible for the attachment of osteoclast at 
the site of bone resorption either by direct contact or by chemical activity.   
They synthesise organic intercellular substance and produce number of 
growth factors like TGF- β, IL-1, TNF-α and IL-6 which regulate bone growth and 
differentiation. The osteoblast differentiates into osteocyte in the lacunae of the 
intercellular substance. 17 
The critical factors involved in activation, proliferation, growth and 
differentiation of osteoprogenitor cells  into osteoblasts include bone 
morphogenetic protein, basic fibroblast growth factor, insulin like growth factor (I 
& II ), transforming growth factor β 1 & β 2 and platelet derived growth factor.18 
OSTEOCLAST : 
The osteoclasts are exclusively bone resorptive cells and they are 
multinucleated giant cells varying in size and number of nuclei. They are 
hematopoietic in origin belonging to monocyte -macrophage family. 
  
The cytokines namely Macrophage Colony stimulating factor            (M-
CSF) and Receptor Activator of Nuclear Factor –κ B ligand           (RANK-L) of 
Tumor Necrosis Factor super family are produced by the bone marrow stromal 
cells and osteoblasts. These cytokines are essential for osteoclastogenesis.19 
INORGANIC MATERIALS: 
Inorganic phase contains 65% crystalline materials- hydroxy apatite crystals, 
amorphous calcium phosphate, trapped ions like citrate, flouride, sodium, 
magnesium and potassium. 
WATER: 
Water is present  either intracellular, extracellular or in bone crystals.  
BONE REMODELLING CYCLE: 
           In adult skeleton, bone remodelling occurs to maintain the skeletal integrity. 
It is a bone regenerative process that aims to remove the old bone having high 
mineral density and increased prevalence of fatigue fractures and replace it with 
new bone with low mineral density and better mechanical properties. 20 
        
  
  
Bone is not a dead tissue, instead the constituent parts are constantly being 
removed with the whole body turnover rate of 10% per year. Bone is a dynamic 
structure that undergoes continuous cycles of remodelling consisting of resorption 
followed by deposition of new bone.21  
         Resorption and formation of bone do not occur randomly in skeleton, but 
rather takes in bone multicellular units.22  Bone remodelling cycle usually begins in 
response to a stimulus –partly in response to the effect of parathyroid hormone 
which results in multiplication of the precursor cells and the formation of 
osteoblasts. 23 
Bone remodelling has the following  primary functions 
  
 To repair micro damage within the skeleton to preserve the skeletal 
integrity. 
 To regulate serum calcium level by providing calcium from the skeleton 
via bone resorption. 
 To maintain bone mass. 
The bone remodelling unit has a characteristic life cycle which is divided into four 
distinct phases: 
 Activation 
 Resorption 
 Reversal 
 Formation 
QUIESCENT PHASE: 
       In adult man, approximately 90% of free bone surface is inactive with 
respect to remodelling. During quiescent phase, the bone surface is covered by a 
thin layer of flattened cells. Its function is to protect the bone surface from 
osteoclastic resorption.24 
 
 
 
  
ACTIVATION: 
Bone remodelling is initiated by activation of osteoclasts by various 
systemic hormones like parathyroid hormone, 1,25 –dihydroxy vitamin D3, sex 
steroids and glucocorticoids. These hormones indirectly stimulate the osteoclasts  
by causing the release of  factors from osteoblasts like cells.                      
 This is the conversion of small area of bone surface from quiescent phase to 
resorption phase. In an average adult human skeleton activation occurs 
approximately every 10 seconds. Osteocytes detect and communicate the 
mechanical and chemical changes of the surrounding bone matrix to the lining 
cells on the surface. On receiving signals from these mechanosensor cells lining 
cells then retract from each other exposing a denuded bone surface that 
chemoattracts osteoclast precursors. 9 
RESORPTION: 
       Mature osteoclasts  has an apical membrane domain, with ruffled border that 
play a major role in bone resorption.  Across the ruffled border a proton 
translocating ATPase shuttles the protons  in to the resorption area. This reduces 
the local pH to 4.5or less, thus increasing the solubility of hydroxy apatite crystals 
and allowing demineralisation to occur. 
  
 Local acidic environment promotes the release of lysosomal acid proteases  
that digest the accesible matrix . 21 When the cavity has reached the depth of 50-
100 µm local resorption occurs. Generally bone resorption is rapid and a resorption 
pit is made within 10-14  days. 
 
REVERSAL PHASE: 
 During this period, the osteoclastic resorption surface is smoothened by 
mononuclear cells and a thin layer of mineral rich cement substance is deposited. 
The osteoblastic precursors assemble prior to bone formation. 
 
 
  
FORMATION PHASE : 
 Bone formation occurs in two stages. Soon after the cementing substance 
has been deposited, the newly formed osteoblasts begin to deposit a layer of 
unmineralised bone matrix which is referred to as “osteoid seam”. After 
deposition, the collagen fibrils make the matrix aggregate and cross link before 
they become mineralised. The new matrix begins to mineralise after one week. 24 
GENDER DIFFERENCES IN REMODELLING  25, 26, 27 
The skeletal architecture in male have a different morphology from female 
that set them at lower risk for developing osteoporosis. The increased diameter of 
bone in men provides a greater moment of inertia, which is a strong determinant of 
torque strength. Additionally, men have greater muscle mass which gives them 
more agility and padding in case of fall. 25 
 In men, ageing results in a gradual decrease in the efficiency with which the 
osteoblasts refill the resorption cavities. Consequently the thickness of cancellous 
bone gradually declines which in turn leads to trabecular bone thinning with a 
linear reduction in the bone volume. Although the individual trabeculae are 
thinner, the trabecular connectivity is generally preserved. 
In female, till menopause there will be gradual thinning of trabeculae and 
then there is an abrupt acceleration in the rate of bone loss. This accelerated bone 
  
loss persists for about 5-10 years and is accompanied by a dramatic increase in the 
bone turnover rate. The rapid bone loss experienced after menopause is not the 
result of osteoblastic insufficiency but rather is due to increased osteoclastic 
activity.   
Incidence of fracture risk varies between men and women and it is due to 
their difference in their areal BMD, bone size geometry and bone strength.  
 
  
PARACRINE MOLECULAR MECHANISM THAT REGULATE 
OSTEOCLAST FORMATION AND FUNCTION 
 There are several signalling pathways that regulate bone homeostasis. 
One such pathway involves 
 Transmembrane receptor –RANK (Receptor Activator for Nuclear Factor 
Kappa B) which is expressed in osteoclasts precursors. 
 RANK Ligand (RANK-L) which is expressed in osteoblasts and marrow 
stromal cells. 
 Osteoprotegrin (OPG), a secreted decoy receptor by osteoblasts that can 
bind RANK-L and thus short circuits its interaction with RANK. 
When stimulated by RANK-L, RANK signalling activates the transcription factor, 
Nuclear Factor kappa B which is essential for generation and survival of 
osteoclasts. 28, 29 
A second important pathway involves M-CSF produced by osteoblasts and 
M-CSF receptor expressed by osteoclast progenitors. Activation of M-CSF 
receptor stimulates tyrosine kinase activity that is crucial for generation of 
osteoclasts. 
The other notable pathway involves WNT/ β Catenin pathway. 
  
WNT proteins produced by marrow stromal cells bind to LRP-5 and LRP-6 
receptor (LDL receptor related protein 5 & 6) on osteoblasts and triggers the 
activation of β-Catenin and the production of Osteoprotegrin.4  
 Activating mutations of the low density lipoprotein receptor related protein 5 
leads to high bone mass, where as inactivating mutations leads to osteoporosis 
psudoganglioma syndrome, a condition leading to low bone mass in children.30 
 
 
 
 
 
  
ROLE OF ESTROGEN IN BONE METABOLISM 
Estrogen has three fundamental effects on bone metabolism: 
 It inhibits the initiation of new basic multicellular units  and the activation of 
bone remodelling. 
 It reduces bone resorption by inhibiting the differentiation and activation of 
osteoclast and promotes apoptosis of osteoclasts. 
 It stimulates the commitment and differentiation and prevents apoptotis of 
osteoblastic cells, thereby maintaining bone formation at the cellular level.31  
In bone metabolism, estrogen  mediates its effects through two estrogen 
receptors. Like other steroid hormones, the receptors for estrogen  are protein 
molecules present in the cytosol. These receptors are ligand dependent 
transcription factors. Upon ligand binding, they dimerize and translocate in to the 
nucleus where together with variety of transcription factors they induce or repress 
the transcription of genes.26 
There are two different estrogen receptors 
(i) Estrogen receptor α –classic receptor 
(ii) Estrogen receptor β 
  
Estrogen  receptor α and β are present in most of bone cells with estrogen 
receptor α expression prominent in cortical cells and estrogen receptor β in 
trabecular cells.32 
 Estrogen receptor-related receptor α (ERR -α) is seen in bone cells with 
sequence homology to ER α and ER β. This receptor is an orphan nuclear receptor. 
Despites its inability to interact with estrogen, this receptor binds with Erα /Erβ or 
act directly to alter bone cell function.10  
Estrogen exerts direct antiosteoclastic effects at several stages of osteoclastic 
differentiation and function. Estrogen directly inhibit the formation of 
multinucleated osteoclasts by suppression of RANKL induced activation of 
precursor cells.  
Estrogen binds to the receptor on osteoclast and downregulate bone 
resorption by osteoclasts by altering the activity of lysosomal enzymes. Estrogen 
also affects the ion transport in osteoclast, mainly involving the inward rectifying 
K+ channel at the plasma membrane of the osteoclasts leading to depolarisation of 
plasma membrane which in turn reduces the proton secretion in to the resorption 
lacunae and thereby inhibit resorption.32  
Estrogen also increases TGF-β leading to osteoclast apoptosis and increases 
Osteoprotegrin which blocks the formation and activity of osteoclast.33 Further, 
  
estrogen blocks the synthesis of proinflammatory cytokines by bone marrow and 
bone cells.34   
Thus, Estrogen negatively regulates the number and activity of osteoclast 
and the loss of this direct function potentially play a role in postmenopausal 
osteoporosis. 
CLASSIFICATION OF OSTEOPOROSIS 
On the basis of modified classification by Nordin (1964) which takes in to 
the account of the findings by WHO –osteoporosis can be generalised or localised. 
GENERALISED OSTEOPOROSIS 
 Primary osteoporosis 
Secondary osteoporosis 
PRIMARY OSTEOPOROSIS 
TYPE-I PRIMARY POSTMENOPAUSAL OSTEOPOROSIS 
Postmenopausal osteoporosis which occurs due to loss of ovarian function, 
reflects an absolute acceleration in the rate of bone resorption due to increased 
osteoclast recruitement. 35 
  
  Estrogen deficiency primarily affects the trabecular bone than the cortical 
bone because the former has considerably larger surface area (80% of the total 
area).  The loss of trabecular connectivity associated with increased turn over after 
menopause may be responsible for bone fragility. 25 
TYPE-II SENILE OSTEOPOROSIS 
 Type-II  senile osteoporosis occurs both in men (65-70 years) and in women 
(50 years). Patients with senile osteoporosis have accelerated bone loss of 2% per 
year, with symptoms of osteoporosis beginning when 30% of bone is lost.36  Loss 
of both cortical and trabecular bone occur in senile osteoporosis with increased risk 
of  fracture  hip, pelvis and vertebra. 
SECONDARY OSTEOPOROSIS 37, 38 
MEDICATIONS 
1.Glucocorticoids 
2.GnRH agonist 
3.Loop diuretics 
4.Methotrexate 
5.Heparin 
6.Thyroxine (over replacement) 
 
  
HEREDITARY / SKELETAL / CONNECTIVE DISEASES 
1.Osteogenesis imperfecta 
2.Rickets 
3.Hypophosphatesia  
4.Marfans syndrome 
ENDOCRINE AND METABOLIC CAUSES 
1.Hypogonadism  
2.Hyperthyroidism 
3.Hyperparathyroidism 
4.Cushing‘s syndrome 
5.Gaucher ‘s disease 
6.Hemochromatosis 
7.IDDM 
MARROW DISEASES 
1.Myeloma 
2.Mastocytosis 
3.Thalassemia  
4.Leukemia 
  
RHEUMATOLOGICAL DISORDERS 
1. Systemic lupus erythematosis 
2. Ankylosing spondylitis  
3. Rheumatoid arthritis 
MISCELLANEOUS 
1. Renal insufficiency 
2. Chronic obstructive pulmonary disease 
3. Anorexia nervosa 
4. Malnutrition 
5. Malabsorption 
6. Cystic fibrosis 
7. Coeliac disease 
8. Peptic ulcer 
9. Crohn’s disease 
10. Breast cancer treated with aromatase inhibitors. 
LOCALISED SECONDARY OSTEOPOROSIS 
1. Prolonged immobilisation 
2. Monoarticular Rheumatoid arthritis 
3. Sudeck ‘s osteodystrophy. 
  
PRIMARY POSTMENOPAUSAL OSTEOPOROSIS 39, 40 
           Postmenopausal osteoporosis is an exaggerated form of physiological bone 
depletion that normally accompanies ageing and a loss of gonadal activity. Two 
overlapping phases are recognised. 
HIGH TURN OVER OSTEOPOROSIS 
 Early postmenopausal syndrome characterised by rapid bone loss 
predominantly due to increased osteoclastic resorption. 
LOW TURN OVER OSTEOPOROSIS 
 This is a less well defined syndrome which emerges in elderly people due to 
gradual slow down of osteoblastic activity and the increasing effects of dietary 
insufficiency, chronic ill health and reduced mobility. 
PEAK BONE MASS 
Bone formation continues at pace faster than bone resorption until maximum 
bone strength is reached around the age 30.41  Peak bone mass can be defined as 
highest level of bone strength achieved  in an individual following  normal growth. 
 
Factors determining peak bone mass include 
  
 Genetic 
 Hormonal 
 Environmental 
 Mechanical loading. 42 
Ageing is the major risk factor, because after 35-40 years of age, bone 
resorption slightly exceeds bone formation so that approximately 1% of skeletal 
bone is lost per year. In women the decrease in sex steroids at menopause 
accelerates the bone loss to about 2% per year for the first five years and then 
declines to 1% loss per year.43, 44  
RISK FACTORS FOR POST MENOPAUSAL OSTEOPOROSIS 
GENETIC  FACTORS 
1. Family history of osteoporotic fractures. 
2. Whites  > blacks. 
3. Absence of generalised osteoarthritis 
ANTHROPOMETRIC 
1. Small statured. 
2. Fair thinned pale skin. 
3. Thin body habitus. 
  
HORMONAL FACTORS 
1. Women > men 
2. Early menopause and late menarche 
3. Nulliparity 
DIETARY 
1. Low dietary calcium. 
2. Excess protein. 
LIFE STYLE CHANGES 
1. Sedentary 
2. Smoking 
3. Alcoholism. 
CONCURRENT ILLNESS AND DRUGS 
1. Gastrectomy. 
2. Hyperparathyroidism. 
3. Hyperthyroidism. 
  
4. Rheumatoid arthritis. 
5. Cushing ‘s syndrome. 
6. Corticosteroid therapy. 
7. Neurological diseases-Parkinsonism 
8. Cerebro vascular accidents 45, 46 
GENETIC CAUSE: 
Genetic osteoporosis refers to the concept that osteoporosis is frequently a 
manifestation of genetic disorder. Hereditary plays a role by determining the peak 
bone mass that a woman will attain during her life. African and American women 
have high bone mass than white women and this explains the low risk of 
osteoporotic fractures observed in African-American women. 47 
Numerous genes regulate skeletal growth, peak bone mass, body size while 
others control skeletal structure and density. The candidate genes include those 
encoding collagen type 1α 1,estrogen and vitamin D receptor, TGF-β, insulin like 
growth factor, apolipoprotein E, IL-6 and bone morphogenetic protein. The effects 
of these genes are hormonally modulated, which are themselves genetically 
regulated.48  
  
A polymorphism in SP1 binding site of collagen α-1 gene promoter is 
associated with the phenotype of low bone density and increased propensity to 
fracture in old age without the more severe manifestations of classical osteogenesis 
imperfecta.  
MECHANISM OF OSTEOPOROSIS MEDIATED BY COL1A1 SP1 
POLYMORPHISM 
The COL1A1 SPI T allele has increased affinity for SPI binding and the 
COL1A1 mRNA abundance is increased. This causes an imbalance in the ratio of 
α1 and α2 chains probably resulting in collagen 1 α1 homotrimer this adversely 
affects the mineralisation, reduces bone strength and predisposes to osteoporotic 
fracture. 33 
Linkage analysis suggests that there multiple genes involved in osteoporosis. 
  G to T polymorphism in the regulatory region of COL1A1 gene is 
significantly related to bone mass and risk of osteoporotic fractures in 
postmenopausal osteoporosis. 
 Early onset osteoporosis is associated with mutations in COL1A1 gene on 
17q and COL1A2 gene on 7q. 
 Polymorphisms in genes coding for vitamin D receptor  and calcitonin 
receptor  (CALCR) also contribute to genetic risk for osteoporosis.49  
  
High serum homocysteine levels have adverse effects on bone methyl tetra 
hydro folate reductase which in turn affects methylation of homocysteine to 
methionine and  may negatively affect bone density leading to osteoporosis.50 
SMALL STATURE AND THIN BUILT HABITUS 
Thin built women are at higher risk than obese women, particularly of their 
low estrogen production, their lower concenteration of circulating estrogen, and the 
decreased mechanical stress on their bone.51  
HORMONAL CHANGES 
During Postmenopausal  period  estrogen deficiency is due to either waning 
of ovarian function or amenorrhoea. The rapid bone loss experienced after 
menopause is due to enhanced osteoclastic activity and an overall increase in the 
bone remodelling. IL-6and TNF are the main causative agents underlying bone 
loss induced by estrogen deficiency, mainly by upregulating osteoclast formation 
and activation. 
Following  menopause there is an accelerated  increase in the  production of 
IL-1 and TNF by the monocyte which in turn stimulates stromal cells in the bone 
marrow or their osteoblast progeny to release factors like IL-6, IL-1, Granulocyte 
Macrophage Colony Stimulating Factor,  Monocyte Macrophage Colony 
  
stimulating Factor and RANK-L. These factors in turn stimulate proliferation of 
hamatopoietic osteoclastic precursor cells originating from cells of 
Granulocyte/Macrophage colony forming unit and Monocyte /Macrophage colony 
forming unit lineage to form mature active osteoclasts. 
An increased number of resorption sites are active per unit time and the 
osteoclast dig further into trabeculae and often perforate and further remove them. 
This is due to increase in the life span of osteoclast as a result of decreased 
estrogen level. 48 
Estrogen normally acts as a block to the second messenger from the 
osteoblast to the osteoclast when the former is stimulated by parathormone. Thus 
estrogen deficiency indirectly increases the sensitivity of osteoclasts to Parathyroid 
hormone. 1 
Estrogen normally exerts its beneficial effects by suppressing “Reactive 
oxygen species”. As the Thiol antioxidant defence mechanisms are decreased in 
estrogen deficiency there is a resultant increase in reactive oxygen species may 
induce TNF-α. 10 Estrogen deficiency also results in the intrinsic gut wall defect in 
calcium absorption . 
  
Thus in postmenopusal women decreased estrogen level  via activation of 
various growth factors and inflammatory cytokines affect osteoblastic and 
osteoclastic activity results in negative bone balance and finally osteoporosis. 
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DIETARY CAUSES 
LOW CALCIUM LEVEL52 
Though the principle cause of age related osteoporosis is the continuing 
effects of estrogen deficiency, a further contribution  is also provided by “calcium 
deficiency”. 
The cause of calcium deficiency is complex and is related to age related 
decrease in calcium absorption in the gut and a menopause related acceleration in 
renal calcium excretion. 
The intestinal absorption of calcium is decreased mainly due to reduced 
effectiveness of vitamin D on stimulating calcium absorption. This in turn is due to 
decrease in the precursor of calcitriol, 25 OH vitamin D, due to lack of sunlight 
and of calcitriol itself, due to renal impairment.  
The renal excretion of calcium is increased due to decreased resorption of 
calcium in the distal convoluted tubule associated with the loss of estrogen 
stimulation of Ca++ ATPase. 53. 
The net effect of these two process increases bone resorption via stimulation 
of osteoclastic activity, which in turn is mediated in part by a rise in parathyroid 
hormone level. 
  
 
ROLE OF CALCIUM IN OSTEOPOROSIS 
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OTHER NUTRITIONAL FACTORS 
LOW PROTEIN INTAKE 
Decreased  protein intake has serious effects in the elderly. Malnourished 
individuals with inadequate protein intake are frequently associated with  hip 
fractures. Supplementation of diet with protein has been found to reduce 
complications in hip fracture.9 
In elderly individuals decreased phosphate intake may contribute to bone 
loss. In chronically ill patients or in those who have malabsorption syndrome low 
magnesium levels also accelerate bone loss.  
LIFE STYLE CHANGES 
CIGARETTE SMOKING 
Cigarette smoking for a long period has detrimental effect on bone mass and 
affects the bone mass. These effects are mediated either directly by its toxic effects 
on osteoblasts or indirectly by modifying estrogen metabolism. On an average, 
cigarette smokers normally attain menopause 1-2 years earlier than the general 
population. 
 Cigarette smoking also produces secondary effects that can modulate 
skeletal status like 
  
 intercurrent  respiratory illness 
  decreased exercise  
 poor nutrition  
  the need for additional medications.48 
ALCOHOLISM 
  Alcoholism is the common cause of osteoporosis at all ages, with added 
factor of increased tendency to falls and other injuries. Bone changes seen in 
alcoholism are due to combination of decreased calcium absorption, liver failure 
and toxic effects of alcohol on osteoblast function. 39 
INADEQUATE PHYSICAL ACTIVITYAND SEDENTARY LIFE STYLE 
WOLFF’S LAW (LAW OF TRANSFORMATION OF BONE) 54 
WOLFF ‘S LAW describes the relationship between bone geometry and 
mechanical influences on the bone and the response of bone to stress. Following 
increased load on the particular portion of the bone, the bone will remodel itself 
over time to become stronger to resist that sort of loading. The internal architecture 
of trabeculae undergoes adaptive changes  followed by secondary changes to the 
external cortical portion of the bone which becomes  thicker .The converse is true –
if the loading on the bone decreases ,the bone becomes weaker since there is no 
stimulus for remodelling. 
  
Thus inadequate physical activity and immobilisation results in profound 
bone loss and osteoporotic fractures are aggravated. 
PATHOPHYSIOLOGY OF POSTMENOPAUSAL OSTEOPOROSIS 
The bone strength in an elderly woman is the product of her peak bone mass 
and bone loss .Cessation of estrogen production after menopause results in 
disturbance between bone resorption and bone formation such that the amount of 
bone removed by osteoclast exceeds the rate of new bone formation by osteoblasts. 
As age advances remodelling continues in the same intensity, but due to 
estrogen deficiency the extent of coalescence of pores increases, so the number of 
pores in the cortical bone decreases but the total area of porosity increase. Cortical 
porosity reduces the ability of the bone to limit crack propagation so that the bone 
cannot absorb the energy imparted by fall and this energy is released in the most 
undesirable way, by fracture.55  
 In the bone marrow accumulation of fat occurs because of age related 
decline in the ability of bone marrow cells to differentiate into osteoblast and an 
increased ability to differentiate into adipocytes. 13 
 The characteristic radiological features in osteoporosis is thinning of cortical 
bone and generalised rarefaction of skeleton. The increased osteoclastic activity 
  
mainly affects the bone with increased surface area like cancellous compartment of 
vertebral bodies. In vertebral column there is thinning and disappearance of 
transverse trabeculae followed by thinning of vertical trabeculae finally leading to 
compression fractures and widening of inter vertebral disc resulting in the 
characteristic “FISH MOUTH APPEARANCE”. The lumbar and thoracic 
vertebrae are most commonly affected. 56 
Radiological surveys have shown that 20% of men and 30% of women over 
age 60 have compression fractures of vertebral bodies. Back pain associated with 
height loss and thoracic kyphosis characterised by Dowager’s hump are common 
manifestations. 
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 POSTMENOPAUSAL OSTEOPOROSIS- DIAGNOSIS 
Most of the cases of osteoporosis are not diagnosed, until a fracture occurs. 
A routine spinal radiograph in a symptomatic patient will not detect osteoporosis 
until 40% of bone is lost. Hence a radiograph is not useful in the follow up of 
progression of bone loss in osteoporotic patients. 57 Early diagnosis and 
intervention may produce beneficial results.  
The diagnosis of osteoporosis should  
 Confirm the presence of osteoporosis 
 Rule out secondary causes of osteoporosis 
 Establish a baseline against which patient‘s progress can bemonitored. 
 
 
 
 
 
 
  
METHODS TO DIAGNOSE OSTEOPOROSIS 58 
 Measurement of Bone mineral density 
 Laboratory biochemical markers 
 Bone biopsy with pathological evaluations  
The commonly used technique to diagnose osteoporosis and predict future 
fracture risk is assessment of BMD by bone densitometry which is principally a 
measure of mineral content of bone.BMD measurements strongly correlate with 
load bearing capacity of hip and spine and also with the risk of fracture. 
Bone density evaluation usually incorporates the attenuation of soft tissues 
and bone by x-rays to calculate the BMD. Usually this technique compares the 
patient’s BMD with age and sex matched controls (z-score) and with young adults 
(T-score). 
The values of  bone mineral density is reported either as an absolute value 
and in terms of   “T-Score” which represents the number of standard deviations 
(S.D.) from the young normal mean BMD. For every one SD decrease in BMD, 
the relative risk of fracture approximately doubles. 59 
NATIONAL OSTEOPOROSIS FOUNDATION  (NOF)  recommends that a 
women should be given a bone density test if they meet the following criteria61 
  
 Older than 65 years.  
 Postmenopausal with at least one risk fracture besides menopause or with 
fracture. 
 Considering osteoporosis therapy. 
 On prolonged hormone replacement therapy.  
Since bone quality cannot be measured clinically, calculating osteoporosis with 
low dose x-rays is used for assessing fracture risk in osteoporosis.  
TECHNIQUES FOR MEASUREMENT OF BMD 60, 43  
TECHNIQUE COMMENTS 
Conventional skeletal 
radiography 
Insensitive method. Detects when bone mass loss 
is greater than30%. 
Photon absorptiometry Requires radionucleide source of photons. 
Single energy x-ray 
absorptiometry 
Used in peripheral sites. Cannot be used in axial 
skeleton. 
Dual energy x-ray 
absorptiometry 
Preferred method. Measures total body mineral 
density. 
Computed tomography Used for forearm and spine. High cost and high 
radiation dose. 
Ultrasonography Used for cancellous bone in heal. Advantages are 
low cost, no radiation and easily portable 
  
CONTRAINDICATIONS FOR BONE DENSITOMETRY 
The contraindications include pregnancy, recent gastrointestinal contrast 
studies and radionuclide tests. The results may not be accurate when osteoporosis 
is associated with osteomalacia, osteoarthritis, vascular calcifications and in the 
presence of previous fractures.11  
ULTRASONOGRAPHY 
Ultrasonography is the technique that provides information about the 
mechanical properties of the bone like bone density and bone elasticity which are 
strong predictors of bone strength. 
Techniques used in ultrasound include speed of sound and broad band 
attenuation methods. Speed of sound technique measures bone density and 
elasticity, where as broad band ultrasound attenuation technique measures bone 
density, structure and composition. FOOD AND DRUG ADMINISTRATION 
(FDA) has approved the ultrasound technique to discriminate between normal and 
osteoporotic individuals who are at increased fracture risk.59 
However, the densitometric scan do not reflect the dynamic nature of bone 
tissue. In contrast, biochemical markers of bone turnover provide a better insight of 
bone growth, bone remodelling and their measurement and hence they are useful in 
  
the assessment of metabolic bone diseases like osteoporosis and they provide an 
integrated evaluation of global disease activity rather than assessing a regional 
activity as with densitometric scan.62  
 
BIOCHEMICAL MARKERS OF BONE TURNOVER 
The biochemical bone turn markers reflect the overall rate of bone formation 
and bone resorption and has markedly improved the non invasive assessment of 
bone turn over in metabolic bone diseases like osteoporosis. 63 
Metabolites of bone remodelling which are present in blood and urine serves 
as an effective markers of bone turnover. They appear as a promising tool for 
defining the skeletal status of postmenopausal women. 
  
IMPORTANCE OF BONE TURN OVER MARKERS 64 
 Used in the assessment of bone loss 
A sharp increase in the level of bone mass with negative correlation with 
bone mineral density is associated with increase bone loss. Hence it 
identifies the disease status before overt damage. 
 For assessment of fracture risk 65  
Increased bone resorption is associated with increased risk of vertebral and 
peripheral fractures independent of BMD. 
 For monitoring the treatment response 66  
Antiresorptive therapies such as estrogen, calcitonin and bisphosphonates 
produce a significant  decrease in markers to premenopausal range. 
 Bone turnover markers helps to identify fast bone losers from slow bone 
losers.67  
 In addition to their use in metabolic bone disease, bone turnover  markers 
are potentially useful tools in the diagnosis and monitoring of metastatic 
bone diseases like Prostatic cancer.68  
 Further the assessment of changes in the levels of markers of bone turn over  
will be a useful tool to improve patient persistence.69  
 
  
CLASSIFICATION OF BONE TURN OVER MARKERS 
         Biochemical markers of bone turn over are classified as  bone formation 
markers which are formed from osteoblast and  bone resorption markers  produced 
by osteoclasts. 
 BONE  FORMATION MARKERS 70 
  Alkaline phosphatase  (Bone isoform) 
 Osteocalcin (bone Gla protein) 
 Procollagen type 1 propeptides 
 Bone sialoprotein 
 BONE RESORPTION MARKERS 44 
 Telopeptides  
            N-Telopeptides 
            C-Telopeptides 
 Pyridinium cross links 
• Free deoxy pyridinoline 
• Free pyridinoline 
• Total deoxypyridinoline and pyridinoline 
 Tartrate resistant acid phosphatase 
  
 Hydroxyproline 
More recently,osteoprotegrin and RANK Ligand are also used as markers of bone 
turnover. 
 
MARKERS OF BONE FORMATION 
S.ALKALINE PHOSPHATASE 71 
S.Alkaline phosphatase, an enzyme located in the membranes of osteoblasts 
and  it is released into circulation during bone formation. In the serum the enzyme 
exists in various isoforms derived from liver, intestine and placenta, in addition to 
bone. Hence total Alkaline phosphatase lacks sensitivity and specificity as a bone 
marker.  Bone isoforms exists in three fractions-B/I (70% bone &30% intestine), 
B1, and B2  forms. B1 and B2 forms are identified by high performance liquid 
chromatography. Direct immunoassays using antibodies recogonize the bone 
  
isoenzymes and is found to be more sensitive to detect bone turnover following 
menopause. 
OSTEOCALCIN 
Mature osteoblasts,odontoblasts and hypertrophic chondrocytes  secretes 
Osteocalcin ,a small noncollagenous protein containing 49 aminoacids. It is 
incorporated in to the extracellular matrix of the bone, but a fraction of newly 
synthesised  osteocalcin is released into circulation. Osteocalcin level in serum 
follows a circadian rhythm  characterised by a decline during morning, low around 
noon and gradually increased during evening and night. Osteocalcin is used as a 
clinical index of bone turnover because of its tissue specificity ,wide availability 
and low intra individual variation. But the peptide is rapidly degraded in the serum, 
resulting in intact and fragmented segments in serum. This resulting heterogenicity 
of fragments limits its usage as a marker in serum.44 
PROCOLLAGEN  TYPE 1 PEPTIDE 
Procollagen type1 contains N and C terminal extension which are removed 
during extracellular processing of type1 collagen into aminoterminal(P1NP) and 
carboxyterminal(P1CP) extension peptides before fibril formation. P1NP is useful 
for monitoring the efficacy of anabolic treatment including parathyroid hormones. 
  
  Other protein used as boneturnover markers include osteonectin  and bone 
sialoprotein . 
BONE RESORPTION MARKERS   
N-TELOPEPTIDE 
Type 1 Collagen accounts for 90% of organic matrix of the bone. Collagen 
has triple helix structure with two α 1(I) chains and one α2 (I) chains. Initially it is 
synthesised as procollagen with N and C terminal extensions. Procollagen 
undergoes extensive post translational modifications including hydroxylations of 
proline and lysine residues, glycosylation and formation of interchain and 
intrachain disulphide bonds. The N and C terminal extensions are removed by 
peptidases resulting in  the formation of triple helix. Type 1 Collagen immediately 
assembles into immature fibrils with limited tensile strength andfinally forms 
mature Collagen by intra and inter molecular cross links.72  
During the process of resorption amino and carboxy terminal fragments are 
released. These fragments with attached cross links are called Telopeptides. 
Elevated levels  of N-Telopeptide is seen in postmenopausal women due to 
increased bone resorption. N-Telopeptide is highly specific for bone because DPD 
cross links primarily involves α2 (I)  chains with 2/3rd in the N-Telopeptide region. 
  
 
PYRIDINIUM CROSS LINKS 
Extracellular maturation of Collagen produces pyridinium cross links and 
they are released during bone resorption. Total, free and protein bound PYD and 
DPD can be measured as bone resorption markers. 
  
 
TARTRATE RESISTANT ACID PHOSPHATASE 
Acid phosphatase is the lysosomal enzymes present in bone, prostate, 
platelet, erythrocytes and spleen. Bone acid phosphatase is resistant to tartrate and 
during bone resorption osteoclast produce and release acid phosphatase (isoform 
5b) into circulation.9 
HYDROXYPROLINE 
Hydroxyproline is found in Collagen following post translational 
modification of proline residues and is released into circulation following acid 
hydrolysis. It is not specific for bone because other tissues like muscle and skin 
  
contains significant amount of collagen. Approximately 10% of the total 
production is excreted in the urine as the peptide bound form. 73 
The present study is planned to evaluate the levels of N-Telopeptide in 
postmenopausal women. 
  
 
 
 
 
 
 
 
 
 
 
 
  
AIM AND OBJECTIVES 
       The aim of the study is to measure S.N-Telopeptide , a bone resorptive 
biomarker in postmenopausal women  and to compare it with healthy 
premenopausal women. 
The objectives of this study are 
(I) To correlate Serum N-Telopeptide with Serum Estrogen level. 
(II)  To correlate Serum N-Telopeptide level with Serum Calcium, Serum 
Phosphorus and Serum Total Alkaline phosphatase. 
 
 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
The study was conducted at Thanjavur Medical College Hospital after 
getting approval from the ethical committee. Written informed consent was 
obtained from the participants. 
STUDY GROUP 
Study group included 50 postmenopausal women aged 50-70 years who 
were not previously diagnosed as osteoporosis and who had BMD T-score  ≥  - 2.5 
and T-score between -1.0 to -2.5. 
EXCLUSION CRITERIA 
 Diabetes mellitus 
 Kidney diseases 
 Drugs -steroid 
CONTROL GROUP 
 Control group included 50 premenopausal women aged 25-35 years without 
any specific illness. 
 
 
  
SAMPLE COLLECTION 
 Under aseptic conditions, 5ml of venous blood was collected from each 
subject. The vacutainers containing the blood samples were kept at room 
temperature  for 30 minutes and then centrifuged at 2000g for 15 minutes for clear 
separation of serum. The following parameters were estimated immediately after 
the serum was separated. 
1. Calcium 
2. Phosphorus 
3. Total Alkaline phosphatase 
4. Urea  
5. Creatinine 
6. Glucose 
The remaining aliquot of serum was stored at -20° C in the deep freezer for 
estimation of serum N –Telopeptide and serum Estrogen. 
BMD was assessed by ultrasonography taken in heel and the T-Scores were 
recorded.   
 
  
 
ESTIMATION OF S.N-TELOPEPTIDE 
PRINCIPLE OF THE ASSAY 
The microtiter  plate provided in the kit has been pre coated with an 
antibody specific to N-Telopeptide. Standards or samples are then added to the 
appropriate microtiter plate wells with the biotin –conjugated preparation specific 
for N-Telopeptide  and avidin conjugated to Horseradish peroxidase (HRP) is 
added to each microtiter plate well and incubated. Then a TMB (3,3’,5,5’ tetra 
methyl benzidine ) substrate solution is added to each well. Only those wells that 
contain NTX, biotin-conjugated antibody and enzyme –conjugated avidin will 
exhibit a change in colour. The enzyme-substrate reaction is terminated by the 
addition of the sulphuric acid solution and the colour change is measured 
spectrophotometrically at a wavelength of 450 nm ± 2nm.The concentration of N-
Telopeptide in the samples is then determined by comparing the O.D. of the 
samples to the standard curve. 
 
 
 
 
 
  
MATERIALS PROVIDED 
REAGENT     QUANTITY 
Assay plate      1 
Standard      2 
Sample diluents     20 ml 
Biotin -Antibody Diluent    10 ml 
HRP-avidin Diluent    10 ml 
Biotin Antibody     120 µl 
HRP-avidin      120 µl 
Wash Buffer     20 ml 
TMB substrate     10 ml 
Stop solution     10 ml 
REAGENT PREPARATION 
1. PREPARATION OF WASH BUFFER : 
  Wash buffer concentrate is brought to room temperature. If crystals are 
found in the wash buffer concentrate, mix the buffer gently until the crystals 
dissolve completely. 500ml of wash buffer is prepared by diluting 20ml of wash 
buffer concentrate into deionised or distill water. 
 
  
2. PREPARATION OF STANDARD: 
 The standard vial is centrifuged at 6000 -10,000 rpm for 30 s. A stock 
solution of 500 nM  BCE is prepared by reconstituting the standard vial with 1.0 
ml of sample diluent. The standard is allowed  to sit for a minimum of 15 mins at 
room temperature with gentle agitation prior to making serial dilutions. The 
undiluted standard serves as the high standard (500 nM BCE). The sample  Diluent 
serves as the zero standard (0 nM BCE). Fresh standard is prepared  for each assay  
and used within 4 hours and discarded. 
3. BIOTIN-ANTIBODY:  
Biotin-Antibody conjugate is centrifuged before opening and diluted to the 
working concentration using Biotin – antibody Diluent (1:100). 
4. HRP-AVIDIN : 
The vial is centrifuged  before opening and diluted to the working 
concentration using HRP-avidin Diluent (1:100). 
ASSAY PROCEDURE : 
Bring all reagents and samples to room temperature before use.  
1.  100µl of Standard , Blank, or Sample is added per well. Cover with the 
adhesive strip. Incubate for 2 hours at 37°C. 
  
2. The liquid of each well is removed. 
3. 100µl of Biotin-antibody working solution is added to each well and 
incubated for 1 hour at 37°C. Biotin-antibody working solution may appear 
cloudy. Warm up to room temperature and mix gently until solution appears 
uniform. 
3. The liquid from each well is aspirated and subsequently washed. The whole 
process is repeated three times for a total of three washes. 
Wash:  each well is filled with 200 µl of wash buffer and allowed to stand 
for  stand for 2 minutes, then the liquid  is removed by flicking the plate over 
the sink. The remaining drops are removed by patting the plate over the sink. 
Finally, the remaining  liquid drops are removed by patting the plate on a 
paper towel. For good performance complete removal of liquid at each step 
is essential. 
4. 100µl of HRP-Avidin working solution is added to each well. The microtiter 
plate is then coverd with a new adhesive strip and incubated for 1 hour at 
37°C.  
5.  Aspiration of the wells and subsequent  washing is repeated  five times as in 
step 4.  
  
6.  90µl of TMB substrate is added to each well and Incubated for 10-30 
minutes at 37°C. The plate is kept away from drafts and other temperature 
fluctuations in the dark.  
7.  50µl of Stop Solution is added to each well when the first four wells 
containing the highest concentration of standards develop obvious blue 
colour. If colour change does not appear uniform, gently tap the plate to 
ensure thorough mixing.  
8. The optical density of each well is determined within 30 minutes, using a 
microplate reader set to 450 nm. 
CALCULATION OF RESULTS ; 
A standard curve is constructed by plotting the mean absorbance for each 
standard on the x-axis against the concentration on the y-axis and a best fit curve is 
drawn through the points on the graph. Using the absorbance value for each sample 
the corresponding concentration of N-Telopeptide is calculated from the standard 
curve. 
 
 
 
  
 
  
 
ESTIMATION OF SERUM ESTRADIOL  
Estradiol (E2) is a C18 steroid hormone with a phenolic A ring. It is the 
most potent natural estrogen produced by the ovary, placenta and in smaller 
amounts by the adrenal cortex and the male testes. 
PRINCIPLE OF THE TEST : 
The E2 EIA is based on the principle of competitive binding between E2 in 
the test specimen and E2 -HRP conjugate for a constant amount of rabbit anti-
Estradiol. In the incubation, goat anti-rabbit Ig G-coated wells are incubated with 
25 µl E2 standards,controls, patient samples,100µl Estradiol-HRP Conjugate 
Reagent and 50µl rabbit anti –Estradiol reagent at room temperature (18-25°C) for 
90 minutes. During the incubation, a fixed amount of HRP –labelled E2 competes 
with the endogenous E2 in the standard, sample or quality control serum for a fixed 
number of binding sites of the specific E2 antibody. Thus, the amount of E2 
peroxidase conjugate, immunologically bound to the well progressively decreases 
as the concentration of E2 in the specimen increases. Unbound E2 peroxidase 
conjugate is then removed and the wells washed. Next, a solution of TMB Reagent 
is added and incubated at room temperature for 20 minutes, resulting in the 
development of blue colour. The colour development is stopped with the addition 
  
of 1N HCL, and the absorbance is measured spectrophotometrically at 450nm. The 
intensity of the colour formed is proportional to the amount of enzyme present and 
is inversely related to the amount of unlabelled E2 in the sample. A standard curve 
is obtained by plotting the concentration of the standard verses the absorbance. The 
E2 concentration of the specimens and controls run concurrently with the standards 
can be calculated from the standard curve. 
REAGENTS 
MATERIALS                   QUANTITY 
Goat Anti-Rabbit IgG – coated                           96 wells 
microtiter plate 
Estradiol Reference standards      0.5 ml                       
Rabbit Anti-Estradiol reagent      7ml 
Estradiol-HRP Conjugate reagent     12ml 
Estradiol control -1       0.5ml 
Estradiol control -2       0.5ml 
TMB Reagent        11ml 
Stop solution        11ml 
  
REAGENT PREPARATION : 
1. All the reagents are brought to room temperature  (18-25°C) before use. 
2. Samples with expected Estradiol concentrations over 1000 pg/ml may be 
quantitated by dilution with diluent available from vendor. 
 ASSAY PROCEDURE: 
1.  The desired number of coated wells are secured in the holder . 
2.  25µl of standards, specimens and controls are added into appropriate 
wells. 
3. 100µl of Estradiol-HRP Conjugate reagent is dispensed into each well. 
4.  50µl of Rabbit Anti-Estradiol (E2) reagent is added to each well. 
5.  Mix it thoroughly  for 30 seconds. It is very important to mix them 
completely. 
5. The wells are incubated at room temperature (18-25°C) for 90 minutes. 
6.  The microwells  are rinsed and flicked for 5 times with distilled or de-
ionised water. 
7. 100µl of TMB Reagent is added to each well and gently mixed for 10 
seconds. 
8. The wells are incubated at room temperature (18-25°C) for 20 minutes. 
  
9. Finally, the reaction is stopped by adding 100µl of stop solution to each 
well. 
10. Gently mix for 30 seconds till all blue colour changes to yellow colour 
completely. 
11. Absorbance is read at 450nm with the microtiter well reader within 15 
minutes. 
EXPECTED RANGE: 
MALES        < 60pg/ml 
FEMALES 
POSTMENOPAUSAL      <18pg/ml 
 OVULATING PERIOD 
EARLY FOLLICULAR      30-100pg/ml 
         LATE FOLLICULAR        100-400pg/ml 
         LUTEAL PHASE                60-150pg/ml 
         PREGNANCY                   UPTO 35,000 pg/ml 
         PREPUBERTAL                 <10pg/ml 
 
 
  
CALCULATION OF RESULTS 
1. Calculate the mean absorbance value ( A ₄₅₀) for each set of reference 
standards, controls and samples. 
A  standard curve is constructed by plotting the mean absorbance obtained 
for each reference standard against its concentration in pg/ml on a linear-linear 
graph paper with absorbance values on the vertical or Y-axis and concentrations on 
the horizontal or X-axis. 
The mean absorbance values for each specimen is used to determine the 
corresponding concentration of Estradiol in pg/ml from the standard curve 
The values obtained for diluted samples is further converted by applying the 
appropriate dilution factor in the calculations. 
 
 
 
 
  
  
ESTIMATION OF S.CALCIUM 
METHODOLOGY:  CHEMICAL METHOD -ARSENAZO 
PRINCIPLE: 
Arsenazo III is chemically stable and has high affinity for Calcium in a 
neutral pH range. Arenazo forms a 1:1 violet Arsenazo : Calcium complex with an 
absorbance maximum at 650 nm. The concentration of Calcium is proportional to 
the absorbance of violet coloured Arsenazo III: Calcium complex. The colour 
produced by this complex is stable for at least 8 hours at room temperature. 
REAGENT COMPOSITION: 
REACTIVE INGREDIENTS: 
Arsenazo III    233µmol / L 
Non reactive buffers, stabilizers and fillers. 
TEST PROCEDURE: 
Wavelength : 650nm 
Into a series of matched cuvettes pipette: 
TEST                   1ml reagent + 25 µl sample 
STANDARD        1ml reagent + 25 µl standard 
  
BLANK                 1ml reagent + 25 µl water  
Mix and incubate at room temperature. The reaction is complete within one 
minute. The colour is stable for at least 8 hours. Read the absorbance of the sample 
and standard at 650 nm, adjusting the instrument to zero absorbance with the 
blank. 
CALCULATIONS: 
 
standard of Absorbance
sample of Absorbance
  x concentration of standard =mg/dl calcium 
LINEARITY: 
 The assay is linear upto 15 mg/dl. 
REFERENCE RANGE: 
 8.5-10.5 mg/dl. 
    
 
 
  
 
  
ESTIMATION OF S.PHOSPHORUS 
PRINCIPLE: 
 Phosphate reacts with ammonium molybdate in acid medium to form 
phosphomolybdate complex with yellow colour. The intensity of colour is directly 
proportional to the inorganic phosphate in the sample, the colour formed is 
measured at 340 nm. 
Inorganic phosphorus + Ammonium molybdate        Phosphomolybdate 
INTERFERING SUBSTANCES 
Hemolysed serum will interfere with the assay. 
Glasswares contaminated with detergents will affect the results. 
REAGENTS: 
REAGENT 
NO. REAGENT COMPOSITION CONCENTRATION 
1 Molybdate   
reagent 
Ammonium 
molybdate surfactant 0.3 mM/ L 
2 Sample blank 
reagent 
Sodium chloride 
preservative 154 mM/ L 
3 Phosphorus 
standard 
Potassium dihydrogen 
phosphate 
preservative 
5mg/dl 
 
 
  
PROCEDURE: 
 Reagent Blank Standard Test 
Serum - - 10 µL 
Reagent 3 - 10 µL - 
Reagent 1 1000 µL 1000 µL 1000 µL 
 
Mix well and incubate at 37°C for 5 mins. 
CALCULATION:        
 
standard of Absorbance
sample of Absorbance
  x concentration of standard  =mg / dl Phosphorus 
REFERENCE RANGE: 
CHILDREN                        4.0 – 7.0 mg/dl 
ADULTS                           2.5 – 4.5 mg       
ESTIMATION OF S. TOTAL ALKALINE PHOSPHATASE 
Alkaline phosphatase is present in high concentration in liver, bone, 
intestine, placenta and certain tumors. 
 
  
PRINCIPLE:         
2-amino-2-methyl -1-propanol +  p- nitrophenylophosphate  + H 2O  ALP 
4-nitrophenol+ 2- amino -2- methyl-1- propane  phosphate   
ALP : ALKALINE PHOSPHATASE 
METHODOLOGY: 
The ALP- AMP method is based on the recommendations of German society 
of clinical chemistry. This method utilises 4-nitrophenyl phosphate as the 
substrate. Under optimised conditions ALP present in the sample catalyses the 
following reaction. 
At the pH of the reaction , 4-nitrophenol has a intense yellow colour. The 
reagent also contains a metal ion buffer system to ensure that optimal 
concentrations of zinc and magnesium are maintained. The metal ion buffer can 
also chelate other potentially inhibitory ions which may be present. The reaction is 
monitored by measuring the rate of increase in absorbance at 415 nm which is 
proportional to the activity of ALP in the serum. 
 
 
  
REAGENT COMPOSITION 
ACTIVE REAGENTS   CONCENTRATION 
     AMP buffer pH  9.8         350 mmol/l 
     Mg 2+           2.0mmol/l 
      Zn 2+           1.0mmol/l 
      EDTA           2.0mmol/l 
     p-nitrophenyl phosphate       16.0mmol/l 
WORKING REAGENT PREPARATION: 
Mix 4 parts of R1 with 1 part of R2. Reagents are stable when stored 
between 2-8° C. 
ASSAY PARAMETERS: 
Mode            Kinetic 
Wavelength   405 
Woking reagent volume 1000µl 
Lag time (secs)  60 
No. of readings  2 
  
Kinetic factor  2764 
Reaction temperature 37° 
Reaction direction  increasing 
Normal low   28 
Normal high  111 
Linearity low   0 
Linearity high  1200 
Blank    water 
Units    IU/L 
ASSAY PROCEDURE 
Pipette Sample 
Working reagent 1000µl 
Sample 20µl 
 
Mix well and aspirate 
 
  
CALCULATION: 
ALP activity (IU/L) = ∆A/min X Factor (2764). 
EXPECTED VALUES: 
FEMALES 20-50Y   28 – 78 U/L 
            ≥60              40 – 111 U/L 
MALES 20-50Y   38 – 94 U/L 
  ≥60Y              43 – 88 U/L 
ESTIMATION OF BLOOD UREA 
METHODOLOGY : UREASE METHOD 
Urea is synthesised in the liver as a by product of deamination of amino acids. 
PRINCIPLE : 
The enzyme urease catalyses the hydrolyses of urea into ammonia and 
carbondioxide. In the next reaction glutamate dehydrogenase catalyses the 
conversion of ammonia and α-ketoglutarate to glutamate and water with 
simultaneous oxidation of reduced nicotinamide adenine dinucleotide (NADH) to 
nicotinamide adenine dinucleotide (NAD). For one mole of urea two moles of 
NADH are oxidised.                                                                                                                                 
  
Urease 
Urea + H 2O      →
Urease
    2NH4+ + CO 2 
Glutamate dehydrogenase
 
NH 4+ + NADH+ H ++ 2-Oxoglutarate                   Glutamate +NAD +  
The initial rate of decrease in absorbance at 340nm is proportional to urea 
concentration in the sample. 
REAGENT COMPONENT AND CONCENTRATION: 
R1 Reagent: 
        Α-Ketoglutaric acid            -      99.8 mmol/L 
        Urease                                 -      23.5 KU/L 
        Glutamate dehydrogenase     -      3.5KU/L 
        Adenosine Diphosphate       -      7.6 mmol/L 
        Sodium azide                        -   0.2% 
 
 
  
R2 Reagent: 
NADH             -      2.95 mmol/L 
Sodium azide   -      0.1% 
 
REAGENT PREPERATION AND STORAGE: 
R1 & R2 Reagents are ready to use. Mix 4 volumes of reagent one with 1 
part of reagent two. Reagents are stable when stored at 2-8° C and protected from 
direct sunlight. 
PROCEDURE: 
 BLANK STANDARD TEST 
REAGENT 1.0ml 1.0ml 1.0m1 
STANDARD - 10µl - 
SAMPLE - - 10µl 
 
CALCULATION: 
 ∆A Sample/∆A standard X 50 = mg/dl urea in the sample 
REFERENCE INTERVAL: 15-39mg/dl. 
  
ESTIMATION OF S.CREATININE 
METHODOLOGY :  MODIFIED JAFFE’ S REACTION 
PRINCIPLE : 
Creatinine reacts with alkaline picrate to produce an orange –yellow colour. 
Specificity of the assay has been improved by the introduction of initial rate 
method. The intensity of the orange-yellow colour formed is directly proportional 
to the creatinine concentration and is measured photometrically at 500-520 nm. 
REAGENT COMPOSITION: 
REAGENT : 1 Picric acid reagent 
Picric acid -25.8 mmol/L 
REAGENT : 2 sodium hydroxide reagent 
Sodium hydroxide -95 mmol/L 
Creatinine standard -2mg/dl 
REAGENT PREPARATION: 
Mix equal volumes of reagent 1 and reagent 2.  
Wait for 15 minutes before use. 
  
ASSAY PROCEDURE: 
Pipette Standard Test 
Working reagent 1000µl 1000µl 
Standard 100µl - 
Test - 100µl 
 
Mix well and read initial absorbance (A1) 20 seconds after mixing and final 
absorbance (A2) 80 seconds after mixing. 
CALCULATION : 
∆A = A2 – A1   
Creatinine (mg/dl) =  
standard of Absorbance
sample of Absorbance
 x concentration of standard  
 
LINEARITY : This assay is linear up to 20 mg /dl. 
NORMAL VALUES: 
MALES      : 0.7-1.4 mg/dl. 
FEMALES : 0.6-1.2 mg/dl. 
 
  
ESTIMATION OF BLOOD GLUCOSE 
METHODOLOGY : GLUCOSE OXIDASE PEROXIDASE, 
          END POINT / FIXED TIME 
PRINCIPLE: 
Glucose is estimated by enzymatic method where glucose is oxidised  to  
gluconic acid and hydrogen peroxide in the presence of glucose oxidase. The 
hydrogen peroxide reacts with phenol and 4- aminophenazone in the presence of 
peroxidase to form a red violet quinonemine dye as indicator. 
REAGENT COMPONENT AND COMPOSITION: 
REAGENT 1: Enzyme  reagent –Phophate buffer 50 mmol/L, phenol 15mmol/L, 
4AAP 2.5mmol/L, GOD 18KU/L, POD 2.5KU/L. 
Glucose standard : 100mg /dl (5.54 mmol/L). 
PROCEDURE: 
 BLANK STANDARD SAMPLE 
Sample - - 10 µl 
Standard - 10 µl - 
Reagent 1000 µl 1000 µl 1000 µl 
  
 
Mix and incubate for 5 min at 37°C or 15 min.at R.T. measure absorbance of 
sample (AT) and standard (AS) against reagent blank at 505 nm. 
CALCULATION: 
 
standard of Absorbance
sample of Absorbance
 x concentration of standard = Glucose (mg/dl)  
REFERENCE INTERVAL: 60-110 mg/dl (3.33-6.1 mmol/L) 
 
 
 
 
 
 
 
 
 
  
 
S.NO AGE HT WT BMI N-TELO ESTROGEN BMD RBG UREA CREAT CALCIUM PHOS CaXP ALP
1 36 1.65 65 23.87511 15.63 128 -0.9 97 22 O.7 10.3 3.8 39.14 56
2 35 1.68 55 19.48696 19 164 -1.1 81 26 0.8 9.7 4.2 40.74 62
3 34 1.58 45 18.02596 16.02 88 -0.8 78 18 0.7 10.5 3.7 38.85 48
4 34 1.57 65 26.37024 10.44 146 -0.5 80 24 0.84 10.2 4 40.8 64
5 31 1.5 58 25.77778 14.28 138 -0.7 76 26 1.02 9.3 3.2 29.76 58
6 32 1.55 52 21.64412 18.98 72 -1 99 21 0.7 10.9 3.7 40.33 68
7 34 1.48 55 25.10957 16.72 212 -0.9 120 24 0.89 10 4 40 85
8 30 1.5 42 18.66667 19.23 136 -1 112 20 0.7 9.3 4.2 39.06 75
9 36 1.58 56 22.4323 19.14 168 -1 98 24 1 9.4 3.8 35.72 53
10 28 1.53 58 24.7768 14.78 170 -0.7 96 21 1.1 9.5 4.2 39.9 58
11 29 1.45 50 23.78121 12.14 98 -0.6 97 26 0.8 10.4 3.6 37.44 74
12 31 1.48 45 20.54419 19.3 106 -1 99 24 0.9 9 4.24 38.16 76
13 35 1.45 38 18.07372 19.28 126 -1 104 28 1.1 10.2 2.9 29.58 82
14 27 1.55 46 19.14672 18.76 132 -0.9 94 26 0.82 9.9 3.8 37.62 56
15 30 1.58 54 21.63115 19.42 144 -1.1 90 24 0.8 10.6 2.9 30.74 48
16 32 1.5 53 23.55556 14.36 188 -0.7 85 28 0.9 10.4 3 31.2 47
17 28 1.6 55 21.48438 16.14 196 -0.8 98 20 0.8 10 3.2 32 65
18 34 1.55 68 28.30385 18.02 78 -0.9 96 30 1 9.4 4.1 38.54 70
19 31 1.56 62 25.47666 19.24 121 -1.1 93 27 0.8 9.6 3.4 32.64 62
20 34 1.54 48 20.2395 17.12 94 -0.8 108 20 1.2 9.9 3.8 37.62 76
21 30 1.6 50 19.53125 11.68 139 -0.6 92 28 0.9 10.2 3.2 32.64 82
22 36 1.52 65 28.13366 19.4 158 -1 109 26 0.77 9 4.1 36.9 72
23 32 1.55 57 23.72529 18.43 165 -0.9 82 24 0.9 9.3 3.9 36.27 60
24 29 1.52 54 23.37258 14.16 117 -0.7 84 20 0.89 9.2 4.3 39.56 89
25 28 1.6 59 23.04688 12.02 106 -0.6 90 18 0.7 10.8 2.8 30.24 91
MASTER CHART - I
CONTROL GROUP
  
 
26 32 1.65 65 23.87511 19.87 74 -1.1 86 24 0.9 9.5 3 28.5 62
27 34 1.46 55 25.80221 15.01 122 -0.7 98 20 0.72 10.4 2.8 29.12 80
28 31 1.55 60 24.97399 15.62 98 -0.8 102 26 0.9 9.9 3.4 33.66 74
29 28 1.6 58 22.65625 12.34 130 -0.6 94 32 1 9.4 4.1 38.54 91
30 30 1.58 60 24.03461 14.82 104 -0.7 108 26 0.8 10.2 2.9 29.58 70
31 32 1.62 64 24.38653 15.21 116 -0.8 100 23 0.9 9.8 3.4 33.32 58
32 31 1.6 50 19.53125 14.62 66 -0.7 98 28 1.1 9.5 3.2 30.4 60
33 30 1.45 50 23.78121 19.67 104 -0.7 95 22 0.8 9 4 36 58
34 34 1.5 55 24.44444 25.55 76 -1 86 21 0.7 9.1 3.8 34.58 64
35 32 1.58 52 20.83 17.6 142 -0.9 87 24 0.9 10.2 2.9 29.58 64
36 28 1.56 54 22.18935 19.3 180 -0.8 82 27 0.8 10.5 2.8 29.4 65
37 30 1.55 50 20.81165 17.14 136 -0.9 98 19 0.6 10.3 3 30.9 57
38 34 1.48 51 23.28342 20.11 148 -0.8 94 22 0.9 9.4 3.6 33.84 87
39 35 1.55 53 22.06035 19.98 78 -1.1 90 26 1 9.4 3.4 31.96 64
40 31 1.49 52 23.42237 19.72 114 -1 104 22 1 9 4.1 36.9 69
41 32 1.57 60 24.34176 18.15 86 -1 110 28 0.8 9.1 4.4 40.04 50
42 34 1.58 45 18.02596 16.43 95 0 112 24 0.8 9 4 36 56
43 36 1.65 65 23.87511 24.76 75 -0.8 98 20 0.7 9.1 3.8 34.58 62
44 30 1.58 52 20.83 18.15 172 -0.9 94 22 0.9 9.4 3.8 35.72 48
45 28 1.55 54 22.47659 15.46 142 -0.7 104 20 0.7 9.9 3.9 38.61 64
46 32 1.57 51 20.69049 17.36 122 -0.8 106 26 0.8 9.6 3.4 32.64 58
47 31 1.6 56 21.875 26.51 124 -0.8 110 22 0.8 9.8 3 29.4 74
48 30 1.54 60 25.29938 16.08 116 -0.7 82 26 0.6 10.2 2.9 29.58 76
49 28 1.55 62 25.80645 17.54 143 -0.7 98 21 0.7 10 3.2 32 47
50 33 1.52 61 26.40235 16.83 136 -0.9 94 24 0.6 9.4 3.8 35.72 79
  
 
S.NO AGE SEX HT Wt BMI N-TELO ESTROG BMD RBG UREA CREAT CAL PHOS CaXP ALP
1 55 F 1.6 70 27.344 129.86 10.1 -3.1 95 28 1 9.1 4.5 41 147
2 60 F 1.47 48 22.213 132.62 10.33 -2.8 90 27 0.81 8.8 4.1 36.1 112
3 58 F 1.5 62 27.556 110.42 13.6 -2.7 84 25 0.66 8.6 4.3 37 87
4 60 F 1.5 52 23.111 109.7 14.23 -2.7 102 20 0.72 8.9 4.8 42.7 148
5 65 F 1.45 48 22.83 90.15 16.8 -2.6 105 28 0.88 9.3 4.2 39.1 100
6 60 F 1.45 45 21.403 107.64 14.44 -2.7 105 20 0.7 9.2 3.6 33.1 119
7 60 F 1.5 40 17.778 139.17 10.6 -3.2 108 22 1 9.3 4 37.2 117
8 65 F 1.46 50 23.457 120.83 14.31 -3 87 24 0.97 8.8 4.5 39.6 144
9 59 F 1.52 70 30.298 95.83 10.3 -2.8 106 22 0.75 9 3.9 35.1 135
10 65 F 1.5 58 25.778 93.75 12.9 -3.4 102 23 0.95 8.9 4.3 38.3 76
11 70 F 1.42 40 19.837 105.6 11.3 -2.8 108 18 0.75 8.1 4.1 33.2 112
12 55 F 1.48 46 21.001 90.83 15.56 -2.8 101 21 0.75 9.7 3.5 34 110
13 55 F 1.32 42 24.105 100.69 12.42 -2.8 95 25 0.74 9.1 3.8 34.6 91
14 56 F 1.58 46 18.427 125.83 14.09 -2.9 99 22 0.7 9.9 3.7 36.6 121
15 57 F 1.5 52 23.111 85.42 16 -2.7 95 28 0.8 9 4.2 37.8 84
16 70 F 1.57 48 19.473 93.83 12.4 -3 108 36 1.2 9.2 3.8 35 129
17 55 F 1.54 48 20.24 88.75 15.42 -2.7 102 24 0.54 9 4.1 36.9 68
18 54 F 1.46 70 32.839 70.05 15.6 -2.6 104 28 0.65 10.3 4.5 46.4 76
19 60 F 1.55 47 19.563 113.19 11.42 -3.2 121 38 1.1 9 4.4 39.6 91
20 58 F 1.55 55 22.893 94.52 13.25 -2.8 110 35 1.02 9.7 3.2 31 78
21 65 F 1.5 48 21.333 102.08 11.8 -2.7 114 19 0.76 9.4 4 37.6 136
22 60 F 1.48 45 20.544 97.63 12.8 -2.6 104 23 0.78 10 4 40 144
23 59 F 1.6 59 23.047 103.85 11.63 -2.5 116 21 1.1 9.7 3.6 34.9 114
24 54 F 1.5 58 25.778 85.42 16.45 -2.5 124 32 1.1 9 4.4 39.6 87
25 61 F 1.48 47 21.457 113.32 11.33 -3 111 20 0.84 9 4.6 41.4 109
MASTER CHART - II
STUDY GROUP
  
26 70 F 1.52 67 29 127.37 10.98 -3.3 102 21 0.7 9.6 3.7 35.5 95 
27 58 F 1.51 58 25.44 102.08 12.16 -2.6 93 33 1.02 9.1 4.2 38.2 74 
28 57 F 1.45 50 23.78 86.67 15.82 -2.5 94 24 0.9 9.2 3.8 35 86 
29 56 F 1.55 52 21.64 97.78 12.64 -2.6 103 40 1 10.6 3.2 33.9 70 
30 54 F 1.56 68 27.94 99.87 11.97 -2.7 107 23 0.9 10 3.5 35 144 
31 59 F 1.5 65 28.89 104.47 12.01 -2.8 122 24 1 9.8 3.4 33.3 145 
32 57 F 1.55 58 24.14 98.15 12.48 -2.6 120 25 0.85 9.7 3.8 36.9 76 
33 54 F 1.56 70 28.76 107.48 11.49 -2.8 99 17 0.8 9.6 3.8 36.5 136 
34 55 F 1.54 56 23.61 98.59 12.63 -2.8 106 20 0.86 9.9 4.4 43.6 98 
35 60 F 1.6 54 21.09 89.37 15.86 -2.7 98 19 0.72 9.2 3.7 34 142 
36 58 F 1.52 65 28.13 88.58 14.48 -2.7 109 22 0.77 9 4.4 39.6 90 
37 57 F 1.55 57 23.73 102.08 11.96 -2.8 82 20 0.83 9.3 3.9 36.3 108 
38 55 F 1.58 56 22.43 128.86 10.03 -3 86 20 0.7 9.4 3.2 30.1 87 
39 58 F 1.56 55 22.6 113.42 11.43 -2.9 87 27 0.77 9.4 4.1 38.5 85 
40 59 F 1.55 52 21.64 134.16 10.43 -3.2 79 28 0.9 9.3 3.8 35.3 123 
41 58 F 1.52 50 21.64 102.61 12.01 -2.8 76 22 0.82 9.5 4 38 138 
42 56 F 1.6 65 25.39 70.56 14.01 -2.6 82 24 0.78 9.7 3.7 35.9 75 
43 62 F 1.55 55 22.89 87.38 11.43 -2.5 78 30 0.92 9.9 4.3 42.6 96 
44 68 F 1.54 52 21.93 101.58 10.15 -2.8 90 20 0.79 9 4.1 36.9 74 
45 62 F 1.63 61 22.96 128.65 11.04 -3 86 24 0.8 8.6 4.3 37 82 
46 55 F 1.53 68 29.05 71.85 17.34 -2.2 84 25 0.86 9.7 3.8 36.9 92 
47 57 F 1.54 68 28.67 68.32 18.65 -2.5 90 34 1 8.4 4.2 35.3 78 
48 54 F 1.5 69 30.67 62.15 17.87 -1.9 96 18 0.72 9.6 4 38.4 106 
49 52 F 1.58 70 28.04 124.31 11.65 -3.1 88 26 0.9 8.2 3.6 29.5 114 
50 54 F 1.57 62 25.15 76.32 17.54 -2.3 95 27 0.7 9.4 3.8 35.7 132 
  
RESULTS & STATISTCS 
TABLE: 1 
GENERAL DESCRIPTIVE STATISTICS OF CONTROL 
AND STUDY  GROUPS 
 
 
Control (n=50) Study (n=50) 
Min Max Mean S.D Min Max Mean S.D 
AGE 27 36 31.58 2.442 52 70 58.82 4.471 
HT 1.45 1.68 1.55 .0542 1.32 1.63 1.522 .055 
Wt 38 68 55.00 6.58 40 70 55.94 8.915 
BMI 18.0 28.30 22.83 2.55 17.7 32.83 24.09 3.47 
N-TELO 10.4 26.51 17.35 3.23 62.1 139.17 101.47 18.39 
ESTRO 66 212 125.78 34.79 10 19 13.14 2.310 
BMD -1.10 .00 -.8240 .1954 -3.40 -1.90 -2.76 .273 
CAL 9.00 10.90 9.76 0.52 8.10 10.60 9.30 .504 
PHOS 2.80 4.40 3.57 0.48 3.20 4.80 3.97 .375 
CaXP 28.5 40.80 34.72 3.89 29.5 46.35 36.90 3.27 
ALP 47 91 66.28 12.0 68 148 105.62 25.0 
RBG 76 120 95.76 9.91 76 124 98.96 12.0 
UREA 18 32 23.80 3.21 17 40 24.84 5.36 
CREAT .60 1.20 .845 .135 .54 1.20 .8456 .138 
  
TABLE: 2 
ASSOCIATION BETWEEN AGE OF THE RESPONDENTS AND THEIR STUDY AND 
CONTROL GROUP 
 
S.NO Age 
Group 
Statistical inference Study 
(n=50) 
Control 
(n=50) 
1 Below 30yrs 0 18 (36%) 
X
2
=100.000 
Df=6 
.0001 < 0.05 
Significant 
2 31 to 35yrs 0 31 (62%) 
3 36 to 40yrs 0 1 (2%) 
4 51 to 55yrs 14 (28%) 0 
5 56 to 60yrs 25 (50%) 0 
6 61 to 65yrs 7 (14%) 0 
7 66 to 70yrs 4 (8%) 0 
 
 
 
 
 
 STATISTICAL ANALYSIS OF N
S.NO N-TELO 
1 Control (n=50) 
2 Study (n=50) 
 
 
 
            COMPARISION OF N
 CONTROL AND STUDY GROUP
0
20
40
60
80
100
120
Control (n=50)
 
TABLE: 3 
-TELOPEPTIDE BETWEEN CONT
GROUPS  
T-TEST 
Mean S.D Statistical inference
17.3504 3.23883 
101.4728 18.39896 
BAR CHART – 1 
-TELOPEPTIDE LEVEL BETWEEN
 
Study (n=50)
N-TELOPEPTIDE 
Control (n=50)
Study (n=50)
ROL AND STUDY 
 
T=-31.840 
.0001<0.05 
Significant 
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TABLE: 4 
-TEST 
Mean  S.D Statistical inference 
125.78 34.793 T=22.841
.0001<0.05
Significant 
13.14 2.310 
BAR CHART -2 
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ESTROGEN 
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Study (n=50)
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TABLE: 5 
STUDENT  
‘
t
’
 TEST FOR ANALYSIS OF BMD IN CONTROL AND STUDY GROUP 
T-TEST 
S.NO BMD Mean S.D Statistical inference 
1 Control (n=50) -.8240 .19542 T=40.827 
.0001<0.05 
Significant  
2 Study (n=50) -2.7660 .27376 
 
 
STUDENT t TEST  FOR ANALYSIS OF BMD IN CONTROL AND STUDY GROUP  
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  TABLE: 6 
R ANALYSIS OF BMI IN CONTROL AND
T-TEST 
 
Mean S.D Statistical inference
22.8383585 2.55797299 T=-2.055
0.043<0.05
Significant 
24.0929245 3.47833764 
BAR CHART – 3 
Study (n=50)
BMI 
Control (n=50)
Study (n=50)
 STUDY GROUP 
 
 
 
 
 
 
  
TABLE: 7 
STUDENT 
‘
t
’
 TEST FOR ANALYSIS OF CALCIUM, PHOSPHORUS AND Ca X P RATIO 
BETWEEN CONTROL AND STUDY GROUP 
 
S.NO   Mean S.D Statistical significance 
1 CALCIUM 
Control (n=50) 9.7620 0.52911 T=4.451 
0.0001 > 0.05 
Significant 
Study (n=50) 9.3020 0.50406 
2 PHOSPHORUS 
Control (n=50) 3.5728 0.48556 T=-1.176 
0.0001 > 0.05 
        Significant 
Study (n=50) 3.9760 0.37502 
3 Ca X P 
Control (n=50)   34.72 3.893 T=-3.040 
0.03 > 0.05 
         Significant 
Study (n=50) 
  36.90   3.279 
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TABLE: 8 
AND STUDY GROUP 
       T-TEST 
 
BAR CHART - 5 
Study (n=50)
Control (n=50)
Study (n=50)
Mean  S.D Statistical inference 
66.28 12.026 T=-10.015
.001<0.05
Significant 
105.62 25.036 
 
 
 
 
 
  
TABLE: 9 
STUDENT 
‘
t
’
 TEST FOR ANALYSIS OF RBG,UREA, AND CREATININE IN CONTROL AND 
STUDY GROUP 
           T-TEST 
S.NO 
  Mean S.D Statistical 
significance 
1 RBG 
Control (n=50) 95.76 9.917 T=-1.453 
.149 > 0.05 
Not Significant 
Study (n=50) 98.96 12.007 
2 UREA 
Control (n=50) 23.80 3.213 T=-1.176 
.243>0.05 
Not Significant 
Study (n=50) 24.84 5.366 
3 CREAT 
Control (n=50) .845 .13573 T=-.022 
.983>0.05 
Not significant 
  Study (n=50) .8456 .13865 
 
 
 
 
 
  
BAR CHART – 6   BLOOD GLUCOSE 
 
BAR CHART -7 UREA 
 
BAR CHART -8 CREATININE 
 
94
95
96
97
98
99
Control Study
23.2
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23.6
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24
24.2
24.4
24.6
24.8
25
Control Study
0.8447
0.8448
0.8449
0.845
0.8451
0.8452
0.8453
0.8454
0.8455
0.8456
Control Study
  
 
TABLE: 10 
ASSOCIATION OF BMD IN CONTROL AND STUDY GROUP 
 
Sl.no BMD 
Group 
Statistical inference 
Study 
(n=50) 
Control 
(n=50) 
1 Less than – 1 0 50 (100%) X
2
=100.000 
Df=2 
.000<0.05 
Significant  
2 - 1 to -2.5 8 (16%) 0 
3 > - 2.5 42 (84%) 0 
 
 
 
 
 
 
 
 
 
  
 
TABLE: 11 
 
PEARSONS CORRELATION BETWEEN N-TELOPEPTIDE 
AND OTHER STUDY PARAMETERS 
 
Study N-TELO Correlation value Statistical inference 
BMI -.372(**) P < 0.01 Significant 
ESTROG -.745(**) P < 0.01 Significant 
BMD -.746(**) P < 0.01 Significant 
CAL -.238 P > 0.05 Not Significant 
PHOS -.015 P > 0.05 Not Significant 
Ca XP -.168 P > 0.05 Not Significant 
ALP .288(*) P < 0.05 Significant 
RBG -.069 P > 0.05 Not Significant 
UREA -.130 P > 0.05 Not Significant 
CREAT .074 P > 0.05 Not Significant 
 
  
 
TABLE: 12 
 
PEARSONS CORRELATION BETWEEN ESTROGEN 
AND OTHER STUDY PARAMETERS 
   
ESTROG Correlation value Statistical inference 
BMI .233 P > 0.05 Not Significant 
N-TELO -.745(**) P < 0.01 Significant 
BMD .648(**) P < 0.01 Significant 
CAL .039 P > 0.05 Not Significant 
PHOS .088 P > 0.05 Not Significant 
CaXP .118 P > 0.05 Not Significant 
ALP -.169 P > 0.05 Not Significant 
RBG .019 P > 0.05 Not Significant 
UREA .108 P > 0.05 Not Significant 
CREAT -.153 P > 0.05 Not Significant 
 
 
  
 
TABLE: 13 
PEARSONS CORRELATION BETWEEN AGE 
AND OTHER STUDY PARAMETERS 
 
Study Age  Correlation value Statistical inference  
BMI -.344(*) P < 0.05 Significant 
N-TELO .233 P > 0.05 Not Significant 
ESTROG -.303(*) P < 0.05 Significant 
BMD -.375(**) P < 0.01 Significant 
CAL -.278 P > 0.05 Not Significant 
PHOS .191 P > 0.05 Not Significant 
CaXP .028 P > 0.05 Not Significant 
ALP .088 P > 0.05 Not Significant 
RBG .114 P > 0.05 Not Significant 
UREA -.068 P > 0.05 Not Significant 
CREAT .138 P > 0.05 Not Significant 
 
 
  
 
TABLE: 14 
PEARSONS CORRELATION BETWEEN BMD 
AND OTHER STUDY PARAMETERS 
 
Study BMD Correlation value Statistical inference 
BMI .292(*) P < 0.05 Significant 
N-TELO -.746(**) P < 0.01 Significant 
ESTROG .648(**) P < 0.01 Significant 
CAL .278 P > 0.05 Not Significant 
PHOS -.061 P > 0.05 Not Significant 
CaXP .104 P > 0.05 Not Significant 
ALP -.103 P > 0.05 Not Significant 
RBG -.025 P > 0.05 Not Significant 
UREA -.006 P > 0.05 Not Significant 
CREAT -.165 P > 0.05 Not Significant 
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RESULTS 
A total of 100 subjects are included in the present study. Out of this, 50 are 
under study group (postmenopausal women with osteoporosis) and 50 are under 
control group (healthy individuals). The values obtained in the control and study 
group are presented in the master chart I and II respectively. 
The serum values of N-Telopeptide,  Estrogen, BMD, Calcium, Phosphorus, 
Total Alkaline Phosphatase, Random blood glucose, urea and creatinine are 
estimated in the control and study group. BMI values and ionic product of Calcium 
and Phosphorus are calculated. 
TABLE :1  
 Shows the anthropometric measurements, the biochemical data, results of  
N-Telopeptide, Estrogen levels and BMD in control and study group. 
In the control group, N-Telopeptide levels are in the range of 10.44 nmol 
BCE/L to 26.51nmol BCE/L with the mean range of 17.35 nmol BCE/L. In the 
study group, N-Telopeptide level ranges between 62.15nmol BCE/L 
to139.17nmolBCE/L with the mean range of  101.47 nmolBCE/L. 
  
In the control group, Estrogen levels are in the range of 66 pg/ml to 212 
pg/ml with the mean of 125.78 pg/ml, where as in the study group the range of 
Estrogen is between 10 pg/ml to 19 pg/ml with the mean range of 13.14 pg/ml. 
TABLE: 2 
 Shows the association between age of the respondents and their study and 
control group. 
TABLE: 3 
  Shows mean N-telopeptide level between control and study group. 
Mean Serum N-Telopeptide in study group is 101.47 ± 18.39 nmolBCE/L 
which is higher than the control group mean 17.35 ± 3.2 nmolBCE/L which is 
statistically significant. (p < 0.0001 ) 
TABLE: 4 
 Shows mean S. Estrogen level between control and study group. 
Mean serum Estrogen level in study group is 13.14± 2.3 pg/ml which is 
lower than control group mean serum Estrogen level 125.78 ± 34.79 pg/ml which 
is statistically significant.(p <  0.0001 ) 
TABLE: 5 
  
 Shows Student ‘t’ test analysis of BMD between control and study group.  
This table shows a statistical decrease in the mean BMD level in study group 
of   -2.766 ± 0 .273 when compared to the mean BMD level in control group of -
0.8240 ±  0.195 which is statistically significant. 
TABLE: 6 
 Shows Student ‘t’ test analysis of BMI between control and study group. 
In this table there is a statistical elevation of mean BMI level in study group 
of 24.09±3.47 when compared with mean BMI level in control group of 22.83 ± 
2.55 which is statistically significant.   
TABLE: 7 
 Shows Student ‘t’ test analysis of S.Calcium, S.Phosphorus and the ionic product 
of calcium and phosphorus between control and study group.  
In this table there is a statistical decrease in mean S.Calcium level in study 
group of 9.30± 0.504 mg/dl when compared with mean S.Calcium level in control 
group of 9.76± 0.529 mg/dl which is statistically significant. 
 Further, there is a statistical increase in mean S.Phosphorus  level in study group 
of 3.976 ± 0.375 mg/dl when compared with mean S.Phosphorus level in control 
group of  3.5728± 0.4855 mg/dl which is statistically significant. 
  
This table shows mean value of ionic product of calcium and phosphorus in the 
study group of 36.9±3.27 which is higher when compared to study group of 34.72± 
3.89 and it is statistically significant. 
TABLE: 8 
 Shows comparison of mean S.Total Alkaline Phosphatase level between control 
and study group. 
Mean Serum Total Alkaline Phosphatase in study group is 105.62 ± 25.03 
U/L which is higher than the control group mean Serum Total Alkaline 
Phosphatase  66.28 ± 12.02U/L which is statistically significant. 
TABLE:9 
 Shows comparison of  mean Random blood sugar, Urea and Creatinine between 
control and study group. 
1. This table shows a statistically insignificant relationship (p value 0.149 > 0.05) 
between mean random blood glucose levels of study (98.96 ± 12.007mg/dl) and 
control group(95.76 ± 9.917mg/dl). 
2. This table shows a statistically insignificant relationship (p value 0.243 > 0.05)  
between mean Urea values of study (24.84 ± 5.36 mg/dl) and control 
group(23.80 ± 3.213 mg/dl). 
  
3. This table shows a statistically insignificant relationship (p:0.983>0.05)  between 
mean Creatinine levels of study  (0.8456 ± 0.138mg/dl) and control group(0.845 
± 0.135 mg/dl). 
TABLE: 10  
Association of BMD between control and study group 
This table shows that the control group(100%)  is normal and 16% of the 
study group is osteopenic and the remaining 84% of study group individual is 
osteoporotic based on BMD which is statistically significant 
TABLE: 11 
  Pearsons correlation between N-Telopeptide and other study parameters. 
This table shows negative correlation between N-telopeptide and Estrogen, 
BMD, BMI and a positive correlation between N-Telopeptide and Total Alkaline 
Phosphatase, which is statistically significant. 
TABLE: 12  
 Pearsons correlation between Estrogen and other study parameters. 
  
This table shows negative correlation between Estrogen and N-Telopeptide  
and a positive correlation between Estrogen and BMD,which is statistically 
significant. 
TABLE: 13 
 Pearsons correlation between Age and other study parameters. 
This table shows negative correlation between Age and Estrogen, BMD and 
BMI which is statistically significant. 
TABLE: 14 
 Pearsons correlation between BMD and other study parameters. 
This table shows positive correlation between BMD and Estrogen, BMI and 
a negative correlation between BMD and N-Telopeptide which is statistically 
significant. 
 
 
 
 
  
  
DISCUSSION 
In the era of increased lifespan and longevity, Osteoporosis is the major 
public health problem. Osteoporosis is the “silent killer”, the individual is usually 
asymptomatic while the disease follows a relentless course. Only the tip of the 
iceberg is noticed and the remaining goes for devastating complications like 
fractures.  
The Gold standard in the diagnosis of osteoporosis is the evaluation of BMD 
by DEXA scan which is not only expensive but also rare in availability. The 
traditional markers of bone resorption like urinary hydroxy proline and calcium are 
not highly specific and sensitive. There is always a need felt to have a reliable, non 
invasive, cost effective, easy accessible and readily available investigation marker 
to diagnose osteoporosis. 
In the present study with 100 subjects, we measured serum N Telopeptide, a 
bone resorptive biomarker to assess the quality of bone in post menopausal women 
and compared it with healthy premenopausal women. The strength of the study lies 
in the fact that both serum N.Telopeptide and BMD measurements were 
simultaneously assessed in elderly population and in normal young female. 
Comparison of mean value of serum N. Telopeptide of the study group 
(101.47 ± 18.39) with that of control group (17.35 ± 3.23) showed a significant rise 
  
in the study group. This shows that there is increased rate of bone resorption 
following menopause. This study also correlates with the previous studies done by 
N. Jayaram et.al. 
Further in our study, we observed that the mean Estrogen level in the study 
group (13.14 ± 2.3) is significantly low when compared to the control group 
(125.78 ± 34.79) and the p value is statistically significant. This result clearly 
supports the pathogenesis that postmenopausal osteoporosis is the hormone 
dependent acceleration of bone loss which occurs after menopause. 
The mean BMD in the study group (- 2.766 ± 0.27) is significantly low 
when compared to that of control group (-0.82 ± 0.195). 
The mean age of the study group is 58.8 years and the mean age of the 
control group is 31.5 years. Pearsons correlation studies showed a positive 
relationship between age and serum N Telopeptide and a negative relationship 
between age and other parameters like BMD and Estrogen. These findings 
supports the fact that the ageing microenvironment also contributes to decreased 
formation of bone due to decreased proliferating capacity of osteogenic cells. . 
Since the mean age of the study is 58.8, this correlates with the current scenario 
that osteoporosis occurs in Indian population 1 to 2 decades earlier than western 
population.74 
  
Within our study group of 50 individuals, 5 individuals have BMI < 20 and 
their serum N Telopeptide levels were significantly high when compared to other 
individuals within the study group. This shows that thin built individuals are at 
high risk of developing osteoporosis than obese individuals. Obese individuals 
have larger body mass which imposes greater mechanical load on bone thereby 
increasing the bone mass. Further adipocytes are important source of estrogen in 
postmenopausal women which inhibits bone resorption by osteoclasts. 
In our study S.Calcium, S.phosphorus and S. Total Alkaline phosphatase 
shows no significant correlation with serum N Telopeptide, which in turn suggests 
that these parameters do not reflect the same aspects of bone metabolism as that of 
serum N. Telopeptide.   
With regard to S.Calcium the blood level is tightly regulated within normal 
limits by Parathyroid hormone otherwise, alterations in the homeostasis of 
S.Calcium  may lead on to life threatening complications.  
Though there is a significant increase in the mean level of S. Total Alkaline 
phosphatase in the study group (105.62 ± 25.03) when compared to that of control 
group (66.28 ±12.02) it cannot be considered as a reliable marker for osteoporosis 
because it is not specific for bone. The blood level of S.Total Alkaline phosphatase 
  
is contributed by various tissues like liver, placenta, intestine in addition to 
osteoblasts of bone. 
 The other parameters like urea, creatinine and random blood glucose does 
not show any possible relationship with primary postmenopausal osteoporosis. 
In the Pearsons correlation analysis the serum N Telopeptide shows 
significant negative correlation with BMD, Estrogen and BMI and a positive 
correlation with S.Total Alkaline phosphatase. 
These observations finally suggests that the level of  S.N.Telopeptide, the 
cross linked collagen peptides increases with bone resorption and can be used as a 
reliable marker in primary postmenopausal osteoporosis. 
 
 
   
 
 
 
 
  
CONCLUSION 
This study shows that there is a significant increase in serum N.Telopeptide 
level in postmenopausal women and it correlates well with the degree of 
osteoporosis. Further, measurement of serum N.Telopeptide also helps to identify 
the individuals having high bone resorption rate and hence increased fracture risk. 
Hence earlier interventional measures both by dietary and pharmacological means 
can be taken to reduce fracture and its complications.   
 
 
 
 
 
 
 
 
 
 
  
LIMITATIONS OF THE STUDY 
Our study has the following limitations 
 Sample size is very small 
 Neither PTH nor Vitamin D, the regulators of mineral metabolism are 
included in the study. 
Further, variations that occur due to seasonal changes - increased bone 
resorption during winter than summer are not considered in the study. 
 
 
 
 
 
 
 
 
 
 
 
  
 
SCOPE FOR THE FUTURE STUDY 
Osteoporosis is a complex, multifactorial, polygenic disease in which 
genetic determinants are modulated by hormonal, nutritional and environmental 
factors. In postmenopausal osteoporosis, deficiency of estrogen plays a major role 
in bone loss. Estrogen regulates bone homeostasis by acting through ER α and ER 
β .These receptors are the members of the nuclear receptor super family which act 
as ligand activated transcription factors. Different polymorphisms have been 
reported in ER α and ER β genes. Studies can be done in future to determine the 
contributions of these polymorphism in the pathogenesis of osteoporosis and also 
to define the functional molecular consequences in the causation of osteoporotic 
phenotype. 
Pharmacotherapy for osteoporosis has been mainly focused on interventions 
that could reverse excessive bone resorption. cDNA analysis studies have shown 
that Cathepsin K, a protease which degrade protein matrix of the bone is expressed 
at high levels in the contact site between osteoclast and bone resorption pit. This 
provides a scope for the development of new antiresorptive drugs like Cathepsin K 
inhibitors in the treatment of osteoporosis.    
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A STUDY OF S.N- TELOPEPTIDE, A BONE RESORPTIVE BIOMARKER 
IN POST MENOPAUSAL WOMAN 
 
PROFORMA 
 
 
NAME OF THE PATIENT  :      O.P.NO/I.P.NO: 
 
AGE/SEX   : 
 
OCCUPATION  : 
 
ADDRESS   : 
 
 
COMPLAINTS   : 
 
PAST HISTORY   : 
 
PERSONAL HISTORY  : 
 
FAMILY HISTORY   : 
 
DRUG HISTORY   : 
 
GENERAL EXAMINATION: 
 
HT:  WT:   BMI:  PR:  BP: 
 
 
SYSTEMIC EXAMINATION: 
 
CVS:      RS: 
  
 
 
P/A:      CNS :  
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1. S.N-TELOPEPTIDE  : 
 
2.  S. ESTROGEN    : 
 
3. S.ALK. PHOSPHATASE  : 
 
4. S. CALCIUM   : 
 
5. S.PHOSPHORUS                           : 
 
6. B. UREA    : 
 
7. S. CREATININE    : 
 
8. B. SUGAR (R)   : 
 
9. BMD                                              : 
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Biochemistry, Thanjavur Medical College, Thanjavur is doing a Study on “A 
STUDY OF SERUM N-TELOPEPTIDE - A BONE RESORPTIVE 
BIOMARKER IN POST MENOPAUSAL WOMEN”. The procedures have 
been explained to me clearly. I understand that there are no risks involved in the 
above procedures. I here by give my consent to participate in this study. The data 
obtained here may be used for research and publication.  
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Place : 
 
